As observed with Leukemia, the number of mortality cases are estimated to increase at a higher rate than the number of newly diagnosed cases (+62% vs. +41%) in the APAC 11 countries.
The higher estimated percentage increase in the mortality cases compared to the newly diagnosed cases (49% vs. 34%) in the APAC 11 countries indicates the need for strengthening healthcare paradigm in the region.
By 2040, CRC incidence is estimated to increase in APAC 11 countries by 73% to approx. 1.2 million. Unfortunately, the mortality related disease burden is expected to be doubled by the year 2040.
When compared to the Rest of the World, a clear spike (>30%) in the mortality related disease burden is expected in the APAC 11 by the year 2040.
By 2040, the mortality-related disease burden in the APAC11 countries will be similar to that in the Rest of the World (RoW), thus, indicating towards the high burden of Cervical cancer in this region.
In APAC 11 countries, the rate of increase in incidence and mortality is expected to be higher (by > 10%) compared to the Rest of the World.